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A rational strategy for the facile and efficent cyclization of amino 
acid-based linear precursors forming nine and twelve-membered 
cyclic peptidomimetics is reported. The resulting chiral lactams can 
readily be reduced to substituted cyclic polyamine analogues of 
1,4,7,10-tetraaza-cyclododecane (cyclen) and 1,4,7-triaza-
cyclononane (TACN). 
The pharmaceutical industry has been treating diseases by 
administering drugs based on small molecules for decades. 
Many small-molecule drugs, however, show only limited 
specificity for their designated targets. Biomimetic therapeutics 
can overcome the shortcomings of small-molecule drugs due to 
their capability of selectively recognizing specific targets in 
highly crowded cellular media. Signalling peptides have crucial 
roles in human physiology1 due to their high affinity towards 
specific cell receptors and consequently, linear peptides have 
been investigated as possible new drug molecules. Generally, 
peptides are considered poor drugs due to their low oral 
uptake, fast metabolization by enzymatic degradation and low 
cell membrane permeability.2 Nevertheless, many peptide 
drugs are on the market due to their low toxicity and superior 
specificity. Especially cyclic peptides have proven to be very 
successful as therapeutic drugs2,3 as most often they show 
enhanced biological activities compared to their linear 
analogues. The structural bias caused by the limited 
conformational flexibility offers favourable binding properties 
by reducing the entropic penalty upon binding.3 Furthermore, 
the lack of both C- and N-termini drastically increases the 
stability towards enzymatic hydrolysis. Finally, some cyclic 
peptides show cell membrane permeability due to specific 
structural features.4 Many of the hurdles associated with both 
linear and cyclic therapeutic peptides can be circumvented 
upon chemical modification of canonical amino acids within the 
polypeptide chain creating peptidomimetics.5 Access to cyclic 
peptide or peptide-like nine and twelve-membered medium 
sized rings is challenging. Cyclization of linear tripeptides is 
notoriously difficult as cyclization can only occur if all peptide 
bonds are in the less favourable cis configuration.6 Cyclization 
proceeds only in moderate to high yields for those linear 
sequences containing strong turn inducers like (proline or 
pseudoproline) or medium turn inducers (side-chain protected 
amino acids e.g. benzyl protected glutamic acid or serine).7 For 
the slightly larger family of twelve-membered cyclic 
tetrapeptides the same problem of bringing both reactive ends 
together arises. Most macrocyclic tetrapeptides 8 contain at 
least one proline (or pseudoproline) 9 residue, a mixture of D- 
and L- amino acids 10 or unnatural amino acids11,12 to facilitate 
the turn. Molecularly imprinted cavities can aid the 
macrocyclization of strained tetrapeptides by enforcing turn 
conformations.13 In general, high dilution conditions are 
required to perform cyclization in solution to prevent 
oligomerizations. Pseudo dilution conditions can be obtained by 
the attachment of the linear precursor on the surface of an 
insoluble polymer14 allowing for increased concentrations and 
simplified experimental procedures. In contrast, cyclic 
peptidomimetics can be accessed by a whole variety of different 
chemical tools including macro lactamization, macro 
lactonization, nucleophilic substitutions and multicomponent 
reactions.8 Furthermore, various transition-metal-catalysed 
reactions offer fast and selective ring-closing reactions.15 
However, such reactions may introduce structural elements 
(e.g. double bonds or triazole rings), not seen in cyclic peptides 
made from natural amino acids. Nevertheless, the increased 
flexibility gained by the introduction of structural elements 
mentioned above, is usually beneficial for the cyclization. On 
the other hand, natural cyclic tri- and tetra- peptides or closely 
related peptidomimetics are potential retrosynthetic 
precursors of 1,4,7,10-tetraaza-cyclododecane (cyclen) and 1,4,7-
triaza-cyclononane (TACN) derivatives. Stereospecifically 
substituted chiral cyclen derivatives are commonly synthesized 
using nucleophilic ring-openings of N-protected aziridines16-18
  
   
Scheme 1 Syntheses of 2S,5S,8S,11S-2,5,8,11-Tetra-methyl-cyclen (M4-cyclen), 2S,5S,8S,11S-2,8,-Diisopropyl-5,11-di-methyl-cyclen (M2P2-cyclen) and 2S,5S,8S,11S-2-
hydroxymethyl-,5,8,11-tri-methyl-cyclen (M3O1-cyclen). Reagents and conditions: (i) Cbz-Cl or Alloc-Cl, Na2CO3, EtOAc/H2O, RT, 1h; (ii); IBX, DMSO, EtOAc, reflux, 2-5h (iii) amine, 
NaBH(OAc)3, CH2Cl2, 20-25°C, 2-16h; (iv) BnBr, K2CO3, MeCN, 40-50°C, 8-16h; (v) PhSiH, Pd(PPh3)4,CH2Cl2, 20-25°C, 4h; (vi) Pd/BaSO4, H2, MeOH, 20-25°C, 4-16h; (vii) HCl in dioxane, 
40°C, 16h; (viii) HATU, DIPEA, MeCN, 20-25°C, 2-4h; (ix) HBr in acetic acid 16 wt. %, 40°C, 30 min; (x) HATU, DIPEA, MeCN, 20-25°C, 20 min.; (xi)  TMS-Cl, LiAlH4, THF/CH2Cl2, 0-5 °C à 
20-25 °C, 3h; (xii) Pd/C, ammonium formate , EtOH, reflux, 16h or Pd/C, H2, MeOH, RT, 16h. 
 
While TACN and substituted analogues are most commonly 
synthesized using nucleophilic ring closing of a linear 
precursor.19,20 Cyclen, TACN and their derivatives are widely 
used in the synthesis of transition metal chelators applied in 
radiopharmacology21, magnetic resonance imagining22 and 
paramagnetic NMR spectroscopy23. Here, we report a synthetic 
strategy towards nine and twelve-membered cyclic 
peptidomimetics based on amino acids or simple derivatives 
which can easily be converted to the corresponding cyclic chiral 
polyamines derivative of cyclen or TACN. 
Initially, we searched for a rational synthesis for 
stereospecifically substituted cyclens omitting the statistical 
oligomerization of aziridines which is extremely tedious to 
scale. Retrosynthetic analysis of M4-cyclen revealed that the 
target compound could be directly synthesized by the reduction 
of cyclic tetraalanine. Traditionally, cyclic tetrapeptides are 
synthesized by an intramolecular ring closing reaction either on 
resin or under high dilution conditions in solution both 
minimizing the formation of oligomers. We synthesized linear 
tetraalanine using standard solution peptide coupling 
conditions and attempted the macrocyclization on a polymer 
support as well as in solution. However, purification and 
isolation of the desired cyclic tetraalanine proved to be difficult 
and the isolated yields were generally low (<5%). We concluded 
that the unfavoured cis conformation of the peptide bond 
required for a successful cyclization severely hinders the 
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formation of the desired cyclic tetrapeptide. Furthermore, we 
observed that cyclic tetraalanine as well as linear tetraalanine 
are highly insoluble compounds limiting the range of applicable 
solvents. Therefore, an alternative strategy based on the 
formation of a bisaminal24 with tetraalaninol was investigated 
due to the increased solubility and flexibility of tetraalaninol 
compared to tetraalanine. Only in the case of glyoxal we 
observed formation of the corresponding bisaminal, but 
subsequent ring-closing proved to be impossible in our hands. 
We therefore tested a combined approach exploiting the 
benefits of both procedures investigated so far using a fast 
peptide coupling as ring-closing step as well as the increased 
flexibility gained by the replacement of amide bonds with 
amines. Our new synthesis of M4-cyclen (c.f. Scheme 1) starts 
with the assembly of the linear tetramer 14 from commercially 
readily available (S)-alanine derivatives. We envisioned a 
convergent approach starting with the N- terminal protection of 
(S)-alaninol with Cbz followed by an IBX mediated oxidation in 
ethyl acetate / dimethyl sulfoxide under reflux.25 Optical puritiy 
(>99%) of the amino aldehyde 1 was determined by chiral HPLC 
(c.f. SI S69). The subsequent reductive amination of 3 with 
alanine tert-butyl ester proceeded in excellent yields without 
epimerization (c.f. SI S73). To avoid side-reactions during the 
second chain elongation step, from a dimer to the tetramer, the 
non-terminal amines were protected using benzylbromide in 
acetonitrile providing access to the corresponding dimer 5. 
Subsequent acidic hydrolysis or hydrogenolytic reduction of 
dimer 5 afford the deprotected dimer 12 or 9, respectively. 
However, we found that the Cbz deprotection could not be 
carried out selectively under all tested conditions using various 
activated and deactivated palladium-based catalysts, solvents, 
temperatures and sources of hydrogen. Therefore, we 
introduced the Alloc protecting group as an alternative which 
offers a third orthogonality and can selectively be deprotected 
in the presence of the benzyl group using phenylsilane and 
Pd(PPh₃)₄. After a HATU mediated peptide coupling between 
the dimers 9 and 12 followed by simultaneous removal of both 
the Cbz and tert-butyl protecting group under strongly acidic 
conditions using hydrobromic acid in acetic acid, the linear 
tetramer 14 was obtained as HBr salt. We found that best 
macrocyclization yields of up to 85% were obtained using HATU 
as peptide coupling reagent and a dilution of 1 g/L in 
acetonitrile. Remarkably, even at concentrations as low as 2 
mM (1 g/L) the formation of the active ester was fast and 
macrocyclization was completed within less than 30 minutes at 
room temperature and no larger oligomers were detected. 
However, we found that in order to avoid N-acetylation and N-
benzylation side reactions, it was crucial to remove traces of 
acetic acid and benzyl bromide from the linear tetramer 14 HBr 
salt by prolonged drying under vacuum at 40°C. Applying a 
trimethylsilyl chloride activated amide reduction26 with lithium 
aluminium hydride followed by a transfer hydrogenation 
affords the macrocyclic compound M4-cyclen in 15 steps with 
an overall yield of 22%. 
We tested the general applicability of this synthetic strategy and 
synthesized two additional chiral cyclen derivatives with 
different substitution patterns and functional groups. M2P2-
cyclen (C2-symmetric) is accessible by the replacement of 
alanine tert-butyl ester with its valine analogue during the 
reductive amination step. Similarly, M3O1-cyclen is obtained by 
replacing the dimer 9 with 11 prior to the second elongation 
step. Surprisingly we found that the Cbz protecting group can 
be selectively removed from dimers 6 and 7 using deactivated 
Pd on BaSO4 under 1 atmosphere of hydrogen omitting the 
need  
Scheme 2 Synthesis of M3TACN. Reagents and conditions: (i) Pd/C, H2, MeOH, 20-25°C, 
4h; (ii) NaBH(OAc)3, CH2Cl2, 20-25°C, 16h; (iii) BnBr, K2CO3, MeCN, 20-25°C, 16h; (iv) HBr 
in acetic acid 16 wt. %, 40°C, 30 min; (v) HATU, DIPEA, MeCN, 20-25°C, 30 min.; (vi)  TMS-
Cl, LiAlH4, THF/CH2Cl2, 0-5 °C à 20-25 °C, 5h; (vii) Pd/C, ammonium formate , EtOH, 
reflux, 16h. 
for an additional protecting group. We attribute this finding to 
the increased steric shielding of the N-benzyl protecting group 
by the larger substituents, causing an increased selectivity 
towards the terminal Cbz protecting group. Therefore, M2P2-
cyclen can be synthesized in a convergent fashion in 11 steps 
with an overall yield of 24%. The asymmetric M3O1-cyclen was 
obtained in 13 steps with an overall yield of 17%. The larger 
substituents proofed to be beneficial for the selective Cbz 
deprotection, however, we observed a decrease in reaction 
rates and lower yields for the macrocyclization step. 
Unfortunately, in addition we observed epimerization during 
the reductive amination in both cases leading to approximately 
8% of unwanted diastereoisomers (c.f. SI S72). Nevertheless, we 
were able to grow single crystals suitable for X-ray analysis for 
all three twelve-membered macrocycles which in combination 
with NMR-spectroscopy prove the correct overall 
stereochemistry of the final product. We found that unwanted 
diastereoisomers formed during the reductive amination are 
  
gradually removed in the following steps. In particular, we 
observed a significant decrease of the unwanted diastereomers 
after the macrocyclization step. We hypothesize that the 
unwanted diastereomers have a less favourable pre-
organization for cyclization. Furthermore, we observed that the 
cyclic unwanted diastereomers were easily separated by flash 
column chromatography at this stage. Inspired by the broad 
applicability of this synthetic strategy we challenged our 
method by applying it to smaller nine-membered triaza cycles. 
We envisioned the linear trimer 27 as the key molecule which 
should allow cyclization in a similar manner as for its larger 
twelve-membered analogue (c.f. Scheme 2). The elongation of 
dimer 24 by one subunit was achieved by Cbz deprotection of 
dimer 23 followed by a second reductive amination step with 
the aldehyde 3, which exclusively favoured the primary amine 
over the secondary amine. The secondary amines were 
subsequently benzyl protected and deprotection of the C- and 
N-termini was achieved quantitatively using hydrobromic acid 
in acetic acid. Cyclization of the trimer 27 under identical 
conditions (1 g/L and HATU) yielded the benzyl protected 
lactam 28 in 63% yield. Although the first reductive amination 
leading to dimer 23 does not lead to epimerization, the second 
reductive amination causes epimerization to a similar extend as 
for M2P2 and M3O1. Similar to the findings presented for the 
twelve-membered macrocycles the unwanted diastereomers 
could be removed quantitatively by flash column 
chromatography of lactam 28. The subsequent reduction and 
transfer hydrogenation steps were carried out accordingly. 
Overall, M3-TACN is accessible in 10 steps in 19% overall yield.  
In conclusion we developed a new rational synthetic strategy 
for the cyclization of linear amino acid-based precursors giving 
accesses to new cyclic peptidomimetics consisting of nine-
membered lactams and twelve-membered bislactams. Due to 
the modular build-up of the linear cyclization precursor a large 
number of different substitution patterns are accessible giving 
rise to novel symmetric and asymmetric cyclic lactams. The 
macrocyclization occurs in solution under moderate dilution 
conditions with high efficiency and yields. We anticipated that 
our method could find application in the synthesis of novel 
cyclic peptidomimetics with potential biological activities. 
Furthermore, the synthesis also provides access to new cyclen 
and TACN based derivatives for future application as high 
affinity metal chelators in paramagnetic NMR spectroscopy, 
magnetic resonance imaging or radiopharmacology. We are 
currently exploring new lanthanide chelating tags based on 
substituted cyclen derivatives. 
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